Structure-based discovery of novel TAOK3 inhibitor via virtual screening, molecular dynamics simulations, and MM/GBSA...

Cancer persists as a leading cause of global mortality, and the mitogen-activated protein kinase (MAPK) pathway plays a pivotal role in tumor progression and drug resistance. Among MAPK regulators, TAOK3 has emerged as a promising therapeutic target due to its oncogenic role in various cancers. Despite its significance, no clinically approved TAOK3 inhibitors exist. In this study we implemented a structure-based virtual screening approach to identify potential TAOK3 inhibitors from a library of 10,000 lead-like compounds. Molecular docking identified ten top-ranked candidates, with compound Z1 (ZINC ID: 77585305) demonstrating the strongest binding affinity (ΔG = -8.42 kcal/mol), outperforming reported inhibitors NCGC00188382 and SBI-581. ADMET profiling confirmed Z1's favorable drug-like properties, including high gastrointestinal absorption and minimal toxicity risks. Molecular dynamics simulations (100 ns) confirmed stable binding of Z1 to TAOK3, as indicated by low RMSD (<0.25 nm), consistent RMSF profiles, and compact radius of gyration. End-state free energy calculations using MM/GBSA also supported favorable binding, with Z1 showing excellent van der Waals interactions (-39.82 kcal/mol). Dynamic cross-correlation matrices and free energy landscape analysis further validated the stability of the TAOK3-Z1 complex. Collectively, these findings highlight Z1 as a promising TAOK3 inhibitor and a potential lead compound for further experimental validation in anticancer drug development.